Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03162783 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03162783 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 51 participants.
The verdict
NCT03162783, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.
Interventions
- DRUG ADX-102 Ophthalmic Solution (0.5%)
- DRUG ADX-102 Ophthalmic Solution (0.1%)
- DRUG ADX-102 Ophthalmic Lipid Solution (0.5%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2017-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03162783
The ClinicalTrials.gov registry entry for NCT03162783 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ADX-102 Ophthalmic Solution (0.5%) is the first listed.
NCT03162783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03162783 about?
NCT03162783 is a clinical study titled "A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome". The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.
What is the current status of trial NCT03162783?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-05-15. Estimated completion is 2017-07-06.
What interventions are being tested in trial NCT03162783?
The interventions under investigation include: ADX-102 Ophthalmic Solution (0.5%) (DRUG), ADX-102 Ophthalmic Solution (0.1%) (DRUG), ADX-102 Ophthalmic Lipid Solution (0.5%) (DRUG).
Who is sponsoring clinical trial NCT03162783?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.